Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells

Gastroenterology

Volumn 124, Issue 2, 2003, Pages 504-520

  Caligiuri, Alessandra ^a   De Franco, Raffaella M S ^a   Romanelli, Roberto G ^a   Gentilini, Alessandra ^a   Meucci, Marta ^a   Failli, Paola ^b   Mazzetti, Luca ^b   Rombouts, Krista ^c   Geerts, Albert ^c   Vanasia, Massimo ^d   Gentilini, Paolo ^a   Marra, Fabio ^a   Pinzani, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d Schwarz Pharma SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 (N ETHYL N ISOPROPYL)AMILORIDE; ALDOSTERONE ANTAGONIST; ANTIFIBROTIC AGENT; CANRENONE; CARIPORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SODIUM PROTON EXCHANGE PROTEIN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL MOTILITY; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; FIBROGENESIS; HUMAN; HUMAN CELL; MITOGENESIS; MUSCLE FIBER CONTRACTION; PHOSPHORYLATION; PRIORITY JOURNAL; STELLATE CELL;

EID: 0037308211     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2003.50058     Document Type: Article

References (62)

1. Gatta A, Sacerdoti D, Bolognesi M, Merkel C. Portal hypertension: state of the art. Ital J Gastroenterol Hepatol 1999;31:326-345.
2. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, Terada H, Ohsuga M, Komeichi H, Tsutsui H. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
3. Nevens F, Lijnen P, VanBilloen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996;23:1047-1052.
4. Garcia-Pagàn JC, Salmeron JM, Feu F, Luca A, Gines P, Pizcueta P, Claria J, Piera C, Arroyo V, Bosch J, Rodés J. Effects of Iow low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994;19:1095-1099.
5. La Villa G, Barletta G, Romanelli RG, Laffi G, Del Bene R, Vizzutti F, Pantaleo P, Mazzocchi V, Gentilini P. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002;35:1441-1448.
6. Sorrentino R, Autore G, Cirino G, d'Emmanuele de Villa Bianca R, Calignano A, Vanasia M, Alfieri C, Sorrentino L, Pinto A. Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings. J Cardiovasc Pharmacol 2000;36:230-235.
7. Cargnelli G, Trevisi L, Debetto P, Luciani S, Bova S. Effects of canrenone on aorta and right ventricle of the rat. J Cardiovasc Pharmacol 2001;37:540-547.
8. Ngarmukos C, Grekin RJ. Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab 2001;281:E1122-E1127.
9. Brilla CG, Maisch B. Regulation of the structural remodeling of the myocardium: from hypertrophy to heart failure. Eur Heart J 1994;15:45-52.
10. Chapman D, Weber KT, Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 1990;67:787-794.
11. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863-1867.
12. Kohler E, Bertschin S, Woodtli T, Resink T, Erne P. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res 1996;33:315-326.
13. Rombouts K, Wielant A, Hellemans K, Schuppan D, Geerts A. Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol 2001;134:224-232.
14. Rombouts K, Niki T, Wielant A, Hellemans K, Schuppan D, Kormoss N, Geerts A. Effect of aldosterone on collagen steady state levels in primary and subcultured rat hepatic stellate cells. J Hepatol 2001;34:230-238.
15. Pinzani M, Gentilini P. Biology of the hepatic stellate cells and its possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999;19:397-410.
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
17. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001;28:1002-1006.
18. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662-667.
19. Oberti F, Pilette C, Rifflet H, Maiga MY, Moreau A, Gallois Y, Girault A, le Bouil A, Le Jeune JJ, Saumet JL, Feldmann G, Cales P. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997;26:1363-1371.
20. Oberti F, Rifflet H, Maiga MY, Pilette C, Gallois Y, Douay O, Le Jeune JJ, Saumet JL, Cales P. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J Hepatol 1997;26:167-173.
21. Yang X, Li X, Wu P, Meng Y, Li S, Lai W. CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis. Horm Res 2000;53:288-293.
22. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured liver fat-storing cells. J Clin Invest 1989;84:1786-1793.
23. Marra F, Gentilini A, Pinzani M, Ghosh Choudhury G, Parola M, Herbst H, Laffi G, Abboud HE, Gentilini P. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's action on hepatic stellate cells. Gastroenterology 1997;112:1297-1306.
24. Casini A, Pinzani M, Milani S, Grappone C, Galli G, Jezequel AM, Schuppan D, Rotella CM, Surrenti C. Regulation of extracellular matrix synthesis by transforming growth factor-betal in human fat-storing cells. Gastroenterology 1993;105:245-253.
25. Weiner FR, Giambrone MA, Czaja MJ, Shah A, Annoni G, Takahashi S, Eghbali M, Zern MA. Ito-cell gene expression and collagen regulation. Hepatology 1990;11:111-117.
26. Pinzani M, Failli P, Ruocco C, Casini A, Milani S, Baldi E, Giotti A, Gentilini P. Fat-storing cells as liver-specific pericytes: spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992;90:642-646.
27. Pinzani M, Gentilini A, Caligiuri A, De Franco R, Pellegrini G, Milani S, Marra F, Gentilini P. Transforming growth factor-β1 regulates platelet-derived growth factor receptor β subunit in human liver fat-storing cells. Hepatology 1995;21:232-239.
28. Marra F, Pinzani M, De Franco R, Laffi G, Gentilini P. Involvement of phosphatidylinositol 3-kinase in action of extracellular signal-regulated kinase by PDGF in hepatic stellate cells. FEBS Lett 1995;376:141-145.
29. Sandirasegarane L, Charles R, Bourbon N, Kester M. NO regulates PDGF-induced activation of PKB but not ERK in A7r5 cells: implications for vascular growth arrest. Am J Physiol Cell Physiol 2000;279:C225-C235.
30. Failli P, Ruocco C, De Franco R, Caligiuri A, Gentilini A, Gentilini P, Giotti A, Pinzani M. Induction of mitogenesis by platelet-derived growth factor in human liver fat-storing cells is dependent upon extracellular calcium influx. Am J Physiol Cell Physiol 1995;269: C1133-C1139.
31. Niki T, Schuppan D, De Bleser PJ, Vrijsen R, Pipeleers Marichal M, Beyaert R, Wisse E, Geerts A. Dexamethasone alters messenger RNA levels but not synthesis of collagens, fibronectin, or laminin by cultured rat fat-storing cells. Hepatology 1996;23:1673-1681.
32. Schuppan D, Dumont JM, Kim KY, Hennings G, Hahn EG. Serum concentration of the aminoterminal procollagen type III peptide in the rat reflects early formation of connective tissue in experimental liver cirrhosis. J Hepatol 1986;3:27-37.
33. Benedetti A, Di Sario A, Casini A, Ridolfi F, Bendia E, Pigini P, Tonnini C, D'Ambrosio L, Feliciangeli G, Macarri G, Svegliati-Baroni G. Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology 2001;120:545-556.
34. Di Sario A, Svegliati Baroni G, Bendia E, Ridolfi F, Saccomanno S, Ugili L, Trozzi L, Marzioni M, Jezequel AM, Macarri G, Benedetti A. Intracellular pH regulation and Na+/H+ exchange activity in human hepatic stellate cells: effect of platelet-derived growth factor, insulin-like growth factor 1 and insulin. J Hepatol 2001;34:378-385.
35. + exchange by platelet-derived growth factor involves phosphatidylinositol 3′-kinase and phospholipase C gamma. J Biol Chem 1994;269:30734-30739.
36. + exchanger 3. J Biol Chem 2001;276:31296-31304.
37. Janecki AJ, Janecki M, Akhter S, Donowitz M. Basic fibroblast growth factor stimulates surface expression and activity of Na(+)/H(+) exchanger NHE3 via mechanism involving phosphatidylinositol 3-kinase. J Biol Chem 2000;275:8133-8142.
38. Tominaga T, Barber DL. Na-H exchange acts downstream of RhoA to regulate integrin-induced cell adhesion and spreading. Mol Biol Cell 1998;9:2287-2303.
39. Belusa R, Aizman O, Andersson RM, Aperia A. Changes in Na(+)-K(+)-ATPase activity influence cell attachment to fibronectin. Am J Physiol Cell Physiol 2002;282:C302-C309.
40. Carloni V, Romanelli RG, Pinzani M, Laffi G, Gentilini P. Focal adhesion kinase and phospholipase C γ involvement in cell adhesion and migration of human hepatic stellate cells. Gastroenterology 1997;112:522-531.
41. Carloni V, Pinzani M, Giusti S, Romanelli RG, Parola M, Bellomo G, Failli P, Hamilton AD, Sebti SM, Laffi G, Gentilini P. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. Hepatology 2000;31:131-140.
42. Li X, Yang X, Wu P, Meng Y, Li S, Lai W. Gene-CYP11B2 expression in rat liver in hepatic fibrogenesis induced by CCl4. Chin Med J 2001;114:64-68.
43. Overdiek HW, Hermens WA, Merkus FW. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 1985;38:469-474.
44. Kojima K, Yamamoto K, Fujioka H, Kaneko H. Pharmacokinetics of-spironolactone and potassium canrenoate in humans. J Pharmacobiodyn 1985;8:161-166.
45. Ho PC, Bourne DW, Triggs EJ, Smithurst BA. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone. Eur J Clin Pharmacol 1984;27:435-439.
46. Merkus FW, Overdiek JW, Cilissen J, Zuidema J. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours. Clin Exp Hypertens A 1983;5:239-248.
47. Marra F, Arrighi MC, Fazi M, Caligiuri A, Pinzani M, Romanelli RG, Efsen E, Laffi G, Gentilini P. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 1999;30:951-958.
48. + exchanger, NHE1: structure, regulation, and cellular actions. Annu Rev Pharmacol Toxicol 2002;42:527-552.
49. + exchange activation by platelet-derived growth factor in rat hepatic stellate cells. Gastroenterology 1999;116:1155-1166.
50. + exchanger (NHE1 isoform) in response to growth factors. J Biol Chem 1997;272:271-279.
51. + exchanger NHE1 and regulates NHE1 activation by platelet-derived growth factor. J Biol Chem 2001;276:31349-31356.
52. Sauvage M, Maziere P, Fathallah H, Giraud F. Insulin stimulates NHE1 activity by sequential activation of phosphatidylinositol 3-kinase and protein kinase C zeta in human erythrocytes. Eur J Biochem 2000;267:955-962.
53. Nakanishi H, Brewer KA, Exton JH. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1993;268:13-16.
54. + antiporter isoforms using amiloride analogs and a new inhibitor exhibiting anti-ischemic properties. Mol Pharmacol 1993;44:1041-1045.
55. + exchange through distinct Cdc42-dependent and RhoA-dependent pathways. J Biol Chem 1996;271:6152-6158.
56. Tominaga T, Ishizaki T, Narumiya S, Barber DL. p160ROCK mediates RhoA activation of Na-H exchange. EMBO J 1998;17:4712-4722.
57. Denker SP, Huang DC, Orlowski J, Furthmayr H, Barber DL. Direct binding of the Na-H exchanger NHE1 to ERM proteins regulates the cortical cytoskeleton and cell shape independently of H(+) translocation. Mol Cell 2000;6:1425-1436.
58. + exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. J Hepatol 1999;30:868-875.
59. Dhawan J, Farmer SR. Induction of collagen synthesis in response to adhesion and TGF beta is dependent on the actin-containing cytoskeleton. Adv Exp Med Biol 1994;358:159-168.
60. Varedi M, Ghahary A, Scott PG, Tredget EE. Cytoskeleton regulates expression of genes for transforming growth factor-beta 1 and extracellular matrix proteins in dermal fibroblasts. J Cell Physiol 1997;172:192-199.
61. St.-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ. Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol 2001;204:1673-1686.
62. Hubner C, Stremmel W, Elsing C. Sodium, hydrogen exchange type 1 and bile ductular secretory activity in the guinea pig. Hepatology 2000;31:562-571.